Perioperative/Adjuvant Atezolizumab in Patients With MSI-high or MMR-deficient Stage III Colorectal Cancer Ineligible for Oxaliplatin-based Chemotherapy - a Phase II Study
Latest Information Update: 22 Aug 2024
At a glance
- Drugs Atezolizumab (Primary) ; IMM 101 (Primary)
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ANTONIO
- 22 Dec 2023 Planned number of patients changed from 120 to 80.
- 10 Jan 2022 Status changed from not yet recruiting to recruiting.
- 02 Nov 2021 Status changed from recruiting to not yet recruiting.